News
The androgen receptor (AR) represents the primary target for prostate cancer (PC) treatment even when the disease progresses toward androgen-independent (AIPC) or castration-resistant (CRPC) forms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback